辉瑞-BioNTech 疫苗接种后意大利圣拉斐尔医院员工队列的 COVID-19 免疫:一项回顾性观察研究。
COVID-19 Immunity in the Cohort of IRCCS San Raffaele Hospital Employees after BNT162b2 Vaccination: A Retrospective Observational Study.
机构信息
Faculty of Medicine, University Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Unit of Medical Specialties and Healthcare Continuity, IRCCS San Raffaele Scientific Institute, Milan, Italy.
出版信息
Ann Ig. 2024 Jul-Aug;36(4):432-445. doi: 10.7416/ai.2024.2615. Epub 2024 Feb 22.
INTRODUCTION
The COVID-19 pandemic represents the most severe health and socioeconomic crisis of our century. It began with the first reports in China, in the Wuhan region in December 2019, and quickly spread worldwide, causing a new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Among the population most at risk of infection and developing severe forms of the disease are the elderly and healthcare workers, who are more exposed to infected individuals. On December 11, 2020, the Food and Drug Administration approved the emergency use of the BNT162b2 vaccine, the first mRNA vaccine in history. Since then, the total number of vaccine doses administered has exceeded 12 billion. Italy was the first European country to be affected by the pandemic, recording the highest number of total COVID-19 cases (25,695,311) and, after the first 70 days, had the highest crude mortality rate (141.0 per 100,000). In this study, we analyze the rate of SARS-CoV-2 infection among healthcare workers at the San Raffaele Scientific Institute in Milan before and after receiving the BNT162b2 vaccine.
STUDY DESIGN
Retrospective observational cohort study.
METHODS
The study analyzed the immunization status of 858 employees of the San Raffaele Scientific Institute in Milan, including doctors, healthcare workers, and administrative staff. The analysis is based on previous studies on the same cohort and is integrated with extrapolation and additional analysis of data from the Preventive Medicine Service's Biobank dataset of the same hospital to estimate the infection rate, duration of the disease, and antibody levels recorded in the personnel before and after receiving the double BNT162b2 vaccination.
RESULTS
The analysis confirms the positive impact achieved by the introduction of mRNA vaccination in reducing the SARS-CoV-2 infection rate and increasing antibody levels in healthcare workers. Although the BNT162b2 vaccination may not provide complete protection against SARS-CoV-2, it appears to be able to reduce the number of infections, particularly the more severe and symptomatic forms often detected in individuals with various risk factors and comorbidities, making them more vulnerable. Healthcare workers, who have extensive contact with patients and record the greatest decrease in the infection rates, represent the population that receives the most benefit from vaccination.
CONCLUSIONS
The evidence suggests that vaccinations are essential in protecting high-risk groups, such as healthcare workers, from SARS-CoV-2 infection. Providing adequate vaccination coverage to healthcare workers limits the spread of infections and decreases the severity of disease manifestations, while also reducing their duration.
简介
COVID-19 大流行代表了我们这个世纪最严重的健康和社会经济危机。它始于 2019 年 12 月中国武汉地区的首例报告,并迅速在全球范围内传播,导致了新型严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的出现。在感染和发展为严重疾病形式风险最高的人群中,包括老年人和医护人员,他们更容易接触到感染个体。2020 年 12 月 11 日,美国食品和药物管理局批准紧急使用 BNT162b2 疫苗,这是历史上第一种 mRNA 疫苗。此后,疫苗接种总量已超过 120 亿剂。意大利是第一个受到大流行影响的欧洲国家,记录了总数最多的 COVID-19 病例(25695311 例),并且在最初的 70 天后,粗死亡率最高(每 10 万人中有 141.0 人死亡)。在这项研究中,我们分析了米兰圣拉斐尔科学研究所医护人员在接种 BNT162b2 疫苗前后感染 SARS-CoV-2 的比率。
研究设计
回顾性观察队列研究。
方法
该研究分析了米兰圣拉斐尔科学研究所 858 名员工的免疫状况,包括医生、医护人员和行政人员。该分析基于对同一队列的先前研究,并与医院预防医学服务生物银行数据集的外推和额外分析相结合,以估计人员在接受双 BNT162b2 疫苗接种前后的感染率、疾病持续时间和抗体水平。
结果
分析证实,mRNA 疫苗的引入对降低医护人员 SARS-CoV-2 感染率和提高抗体水平产生了积极影响。尽管 BNT162b2 疫苗接种可能无法提供针对 SARS-CoV-2 的完全保护,但它似乎能够减少感染数量,特别是在有各种风险因素和合并症的个体中检测到的更严重和有症状的形式,使他们更容易受到感染。与患者广泛接触并记录感染率最大降幅的医护人员是从疫苗接种中受益最大的人群。
结论
证据表明,疫苗接种对于保护高风险人群(如医护人员)免受 SARS-CoV-2 感染至关重要。为医护人员提供足够的疫苗接种覆盖率可限制感染的传播并降低疾病表现的严重程度,同时缩短其持续时间。